Which laboratory value is expected to increase when a client is administered methylprednisolone (Solu-Medrol)?

When a client is administered methylprednisolone (Solu-Medrol), an increase in serum glucose levels is expected. Methylprednisolone is a corticosteroid that influences metabolism in various ways. One of its effects is the promotion of gluconeogenesis and the release of glucose into the bloodstream, which can lead to higher serum glucose levels. This is particularly significant for individuals who may already be at risk for hyperglycemia, such as those with diabetes or prediabetes.

In contrast, methylprednisolone can cause other changes in laboratory values as well, but these do not align with the context of your question. For example, serum calcium levels are likely to decrease due to the drug's propensity to affect bone metabolism. The production of red blood cells may not be directly influenced by methylprednisolone, while serum potassium levels can decrease as well, since corticosteroids can promote urinary excretion of potassium, contributing to the risk of hypokalemia. Thus, the increase in serum glucose is the most characteristic response in this scenario.